The differences in YKL-40 protein serum level between healthy subjects and glioma patients have been demonstrated already in 2002 by Tanwar group13, and a comprehensive analysis of Zhi-Qiang Li14 group confirmed YKL-40 protein being a valuable biomarker for glioma patient prognosis. This evidence concerns the gene CHI3L1 and central nervous system cancer.